Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00176644
Status:
TERMINATED
Last Update Posted:
2023-09-13
First Post:
2005-09-13
Brief Title:
Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer
Sponsor:
University of Medicine and Dentistry of New Jersey
Organization:
Rutgers The State University of New Jersey
Study Overview
Official Title:
Phase II Trial of Transdermal Estradiol in Patients With Hormone Refractory Prostate Cancer
Status:
TERMINATED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Treatment ineffective
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple trials have shown the efficacy of estrogen therapy in metastatic prostate cancer and most recently trials have supported the use of transdermal estrogens patch in the patient population with a decreased risk of cardiovascular disease as compared to the oral estrogens We plan to study the use of transdermal estrogen at a dose of 04mg qd We will evaluate the toxicities and measure quality of life We will assess PSA response and measurable disease response This will be a trial available to the Cancer Institute of New Jersey Oncology Group We will enroll a total of 33 patients We will plan to enroll 10 at CINJPatients will wear the patches 4 continuously We will obtain blood work and clinic evaluations every three weeks We will assess quality of life through a questionnaire given to patient every three weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA072720 | NIH | Cancer Institute of New Jersey | httpsreporternihgovquickSearchP30CA072720 |
| CINJ 080419 | OTHER | None | None |